To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

January 26, 2025

Study Completion Date

February 23, 2025

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

BBT-877

BBT-877 24 weeks + Follow-up 4 weeks

DRUG

Placebo

Placebo 24 weeks + Follow-up 4 weeks

Trial Locations (44)

2050

Royal Prince Alfred Hospital, Camperdown

4006

Royal Brisbane & Women's Hospital, Herston

6009

Institute for Respiratory Health, Nedlands

10475

Myongji Hospital, Goyang-si

13497

CHA Bundang Medical Center, CHA University, Seongnam-si

13620

Seoul National University Bundang Hospital, Seongnam-si

14647

The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon-si

16499

Ajou University Hospital, Suwon

21565

Gachon University Gil Medical Center, Namdong

31151

Soon Chun Hyang University Hospital Seoul, Cheonan

33765

St. Francis Medical Institute - Clinedge, Clearwater

34362

Lady Davis Carmel Medical Center, Haifa

34470

Renstar Medical Research, Ocala

37204

Vanderbilt University Medical Center, Nashville

44281

Meir Medical Center, Kfar Saba

48108

Inje University Haeundae Paik Hospital, Busan

49100

Rabin Medical Center, Petah Tikva

50612

Pusan National University Yangsan Hospital, Yangsan

52621

Sheba Medical Center, Ramat Gan

75020

Premier Pulmonary Critical Care & Sleep Medicine, Denison

76100

Kaplan Medical Center, Rehovot

78278

Tel Aviv Sourasky Medical Center, Ashkelon

90033

Keck Medical Center of USC, Los Angeles

91120

Hadassah Medical Center, Jerusalem

4910000

Barzilai Medical Center, Petah Tikva

85006-2611

Pulmonary Associates P.A., Phoenix

85723-0001

Southern Arizona VA Health Care System - NAVREF - PPDS, Tucson

94304-1207

VA Palo Alto Health Care System, Palo Alto

80206-2761

National Jewish Health Main Campus, Denver

32803-5443

Central Florida Pulmonary Group PA, Orlando

30912-0004

Augusta University, Augusta

60611-2993

Northwestern Memorial Hospital, Chicago

60153-3328

Loyola University Medical Center, Maywood

63017-3632

The Lung Research Center, LLC, Chesterfield

63401-6890

Hannibal Regional Healthcare System-HRMG-Hannibal, Hannibal

29425-8900

Medical University of South Carolina, Charleston

42-500

Centrum Dentystyczno Lekarskie Promedica Joanna Markiewicz, Będzin

85-681

Vitamed Galaj i Cichomski sp.j., Bydgoszcz

06351

Samsung Medical Center, Seoul

02841

Korea University Anam Hospital, Seoul

07345

The Catholic University of Korea - Eunpyeong St. Mary's Hospital, Yeongdeungpo-dong

05505

Asan Medical Center, Seoul

02447

Kyung Hee University Hospital, Seoul

03722

Severance Hospital Yonsei University, Seoul

Sponsors
All Listed Sponsors
lead

Bridge Biotherapeutics, Inc.

INDUSTRY

NCT05483907 - To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF | Biotech Hunter | Biotech Hunter